Outcome of Meeting
GLAXO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
GlaxoSmithKline Pharmaceuticals reported FY2026 consolidated revenue of Rs. 3,82,167 lakhs, up 1.9% from Rs. 3,74,921 lakhs in FY2025. Profit after tax grew 11.7% to Rs. 1,03,598 lakhs from Rs. 92,758 lakhs. The Board recommended a final dividend of Rs. 57 per share (up from Rs. 54 last year), payable from July 1, 2026. Exceptional items of Rs. 2,062 lakhs came from profit on sale of surplus residential properties (Rs. 264 lakhs) and non-operational land (Rs. 1,798 lakhs). Auditors Deloitte Haskins & Sells issued an unmodified (clean) opinion. The company also disclosed Rs. 1,182 lakhs additional employee cost due to new labour code implementation.
Positive results with strong PAT growth and increased dividend signal healthy financial performance. The clean auditor opinion removes any going concern concerns. Exceptional items from asset sales provide one-time gains.